<DOC>
	<DOCNO>NCT01831427</DOCNO>
	<brief_summary>This stagger , placebo-controlled , single multiple ascend dose ( SAD/MAD ) study evaluate safety , tolerability pharmacokinetics GS-5745 participant moderately severely active ulcerative colitis . This study provide valuable data help establish safety , pharmacokinetics efficacy GS-5745 participant ulcerative colitis .</brief_summary>
	<brief_title>Evaluating Safety , Pharmacokinetics Efficacy GS-5745 Adults With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description>The study test safety drug system build trial design ensure participant safety . Participants give different concentration drug ( know `` cohort '' ) start low dose high dose . Single-Dose Treatment : A thorough assessment safety tolerability perform escalate next high dose . For example , first 2 participant dose staggered fashion 24 hour apart . Provided significant safety signal 24 hour post-dose first 2 participant , remain 4 participant dose . A thorough assessment safety tolerability ( day 14 post-dose ) perform safety review committee escalate next high dose . Participants enrol SAD cohort eligible participate MAD adaptive MAD cohort eligibility criterion meet . Multiple-Dose Treatment : This design follow set-up Single-Dose Treatment . Dosing commence first MAD cohort safety data second dose level SAD cohort review Day 15 . Successive MAD cohort dose safety data previous , low dose MAD cohort Day 43 next high dose SAD cohort Day 15 , review safety review committee . An additional Adaptive MAD cohort explore subcutaneous dose GS-5745 150 mg prefilled syringe week 5 week .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male Female , 18 65 year age Negative pregnancy test screening Documented diagnosis ulcerative colitis ( UC ) minimum disease extent 15 cm anal verge Mayo Score least 3 SAD cohort Mayo Score least 6 MAD cohort Hepatic panel ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , total bilirubin , direct bilirubin , alkaline phosphatase , lactate dehydrogenase [ LDH ] ≤ 2 time upper limit normal range [ ULN ] ) Serum creatinine ≤ 1.5 time ULN Hemoglobin ≥ 10 g/dL ( male female ) Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( 1,500 mm^3 ) Platelets ≥ 100 x 10^9/L Pregnant lactate female Exhibit severe UC/ clinically significant active infection Current use oral corticosteroid dose equivalent &gt; 20 mg/day prednisone Any dose adjustment oral corticosteroid oral immunosuppressant ( 6MP , Azathioprine ) , oral 5ASA compound within 30 day Baseline Use rectal formulation 5ASA compound corticosteroid within 2 week prior randomization Crohn 's disease indeterminate colitis History colectomy , partial colectomy , dysplasia biopsy Stool sample positive Clostridium difficile ( C. difficile ) toxin , E. coli , Salmonella , Shigella , Campylobacter Yersinia Treatment Infliximab , Adalimumab , Natalizumab , Golimumab , Vedolizumab Certolizumab within 8 week randomization Any chronic medical condition ( include , limited , cardiac pulmonary disease ) , opinion Investigator , would make individual unsuitable study would prevent compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
</DOC>